Novel T-Cell Receptor Therapy Targets CTNNB1 Mutation, Achieves Complete Tumor Clearance in Preclinical Studies
Key Insights
Researchers at the University of Oslo developed a T-cell receptor therapy targeting the CTNNB1S37F mutation, which affects over 7,000 new cancer cases annually in the U.S.
The engineered T cells demonstrated complete tumor clearance in patient-derived organoids and mouse models, marking the first TCR therapy to show such convincing elimination of solid tumors.
The therapy selectively targets cancer cells carrying the mutation while leaving healthy cells unharmed, offering potential treatment for lung, prostate, and endometrial cancers.
Researchers at the University of Oslo and Oslo University Hospital have achieved a significant breakthrough in cancer immunotherapy by developing a T-cell receptor (TCR) therapy that successfully targets the CTNNB1S37F mutation, a common genetic alteration found in aggressive solid tumors. Published in Nature Immunology, the study demonstrates complete tumor elimination in preclinical models and offers new hope for thousands of patients with lung, prostate, and endometrial cancers.
The CTNNB1S37F mutation occurs in more than 7,000 new cancer cases annually in the United States and is found across several solid tumor types, including endometrial, lung, and prostate cancers. This mutation has historically been challenging to target with conventional therapeutic approaches.
Targeting Public Driver Mutations
The research focuses on what scientists call "public driver mutations" - genetic changes that affect multiple patients rather than being unique to individuals. This approach opens possibilities for developing immunotherapies that can treat groups of patients simultaneously, rather than requiring personalized treatments for each case.
"This CTNNB1S37F mutation is particularly difficult to target with traditional drugs," says Professor Johanna Olweus, senior author and group leader at the University of Oslo and Oslo University Hospital. "Our research shows that we can use engineered immune cells to successfully eliminate tumor cells that carry this mutation."
Engineering T Cells for Precision Targeting
The research team examined blood samples from healthy donors to identify rare T cells capable of recognizing peptides derived from the CTNNB1S37F mutation when displayed by two common human leukocyte antigen (HLA (search)) molecules. These HLA molecules are present in many people, potentially expanding the treatment's applicability to a larger patient population.
"We engineered human T cells to express these specific receptors, effectively reprogramming them to seek out and destroy cancer cells that carry the mutation," explains Maria Stadheim Eggeb\u00f8, Ph.D. student and first author of the study.
The engineered T-cell receptors demonstrated remarkable selectivity, targeting only cells with the cancer-specific mutation while leaving normal cells unharmed - a critical safety feature for any potential therapeutic application.
Complete Tumor Clearance in Patient Models
In preclinical testing, the modified T cells were evaluated against cancer organoids - miniature tumors grown from patient tissue - as well as in mouse models implanted with human tumors. The results showed effective cancer cell elimination in both experimental systems.
"We were especially excited to see full tumor clearance in models derived from human patients," says researcher and co-corresponding author Morten Milek Nielsen. "To our knowledge, this is the first time TCR therapy targeting a mutation has shown such convincing elimination of tumors derived from patients with solid cancers."
Addressing Treatment-Resistant Cancers
The breakthrough is particularly significant given the historical challenges in targeting the pathway influenced by CTNNB1 (search) mutations. Previous strategies have largely failed due to side effects and low specificity.
"What makes our approach different is that we're targeting the actual mutation itself, the root cause, and doing so with precision," says Olweus. "This ensures a targeted attack on cancer cells that leaves healthy cells unharmed."
Implications for Future Cancer Treatment
The findings demonstrate that T-cell receptor therapy can effectively target shared mutations present across various patients and cancer types. Because the CTNNB1S37F mutation is present in many patients, this therapy has the potential to benefit large groups of individuals across multiple cancer types.
"Our findings confirm that TCR T-cell therapy can effectively target shared mutations in solid tumors across various cancer types," adds Eggeb\u00f8. "It's a significant step forward, and we hope it will pave the way for future therapies that can be offered to many patients."
The research team acknowledges that no single mutation appears in all cancer cells, suggesting that combining these TCR T cells with other treatments or targeting additional mutations could provide a more comprehensive approach to cancer treatment.
Looking ahead, the team plans to develop TCR T-cell therapies targeting additional common cancer mutations, which could expand treatment possibilities for larger patient populations and help prevent tumor escape mechanisms.